Keyphrases
Mycobacterium Tuberculosis (M. tb)
100%
Caseum
66%
Tuberculosis
65%
Non-replicating
33%
Tuberculosis Drugs
25%
Drug Tolerance
23%
Pyrazinoic Acid
22%
Fluoroquinolones
21%
Pyrazinamide
21%
Drug Tolerant
17%
SQ109
17%
Pulmonary Lesions
15%
Mycobacterium
15%
Rabbit Model
14%
Drug Candidates
14%
Drug Distribution
13%
Drug Penetration
13%
PanD
13%
Granuloma
12%
Lesion Penetration
12%
Moxifloxacin
12%
Multidrug-resistant Tuberculosis (MDR-TB)
12%
Lung Lesions
12%
L-aspartate-α-decarboxylase
12%
Drug Efficacy
12%
Rifampicin
12%
ADP-ribosylation
11%
Mycobacterium Abscessus
11%
Bacterial Population
11%
Pharmacokinetics
10%
Persisters
10%
Rifabutin
10%
Drug Resistance
9%
Mouse Model
9%
Porin
9%
Rifamycin
8%
Mechanism of Action
8%
Macrophages
8%
Drug Susceptibility
8%
Infection Site
7%
Treatment Shortening
7%
Bacterial Burden
7%
Levofloxacin
7%
Missense mutation
7%
Prodrug
7%
Treatment Response
7%
Clinical Efficacy
7%
Bacillus
7%
Acid Resistance
7%
Necrotic Lesion
7%
Pharmacology, Toxicology and Pharmaceutical Science
Mycobacterium Tuberculosis
64%
Pharmacokinetics
29%
Pyrazinamide
28%
Lung Lesion
27%
Infection
21%
Leporidae
17%
Antibiotics
17%
N (2 Adamantyl) N' Geranylethylenediamine
17%
Pyrazinoic Acid
17%
Drug Distribution
17%
Rifampicin
16%
Pharmacodynamics
15%
Quinolone Derivative
15%
Rabbit Model
14%
Diseases
14%
Lung Disease
14%
Linezolid
13%
Moxifloxacin
12%
Mouse Model
11%
Multi-Drug-Resistant Tuberculosis
10%
Rifabutin
9%
C3HeB/Fe Mouse
9%
Rifamycin
8%
Mycobacterium abscessus
8%
Bedaquiline
8%
Tuberculosis
8%
Clinical Trial
8%
Adenosine Diphosphate
7%
Levofloxacin
7%
Granuloma
7%
Lung Tuberculosis
7%
Prodrug
7%
Oxazolidinone Derivative
7%
Immunopathology
6%
Menaquinone
6%
Mycobacteria
6%
Antibacterial Activity
6%
Aspartic Acid
6%
Carboxylyase
6%
Gatifloxacin
6%
Monotherapy
6%
Tuberculostatic Agent
5%
Multidrug Tolerance
5%
Murine
5%
Ethambutol
5%
Drug Tolerability
5%
Lethality
5%
Hydrophobicity
5%
Synthetase
5%
Amikacin
5%